Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Edgar Gonzalez

General Practice Miami, FL Medical Doctor

NPI 1801132121 CMS profile 728146

7400 Sw 50Th Ter Ste 203, Miami, FL 33155

Open in the dashboard

General payments

$5,150

32 records reported · program years 2019–2025

Research payments

$666

Paid to them · 6 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$3,011,909 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Edgar Gonzalez of Miami, FL is reported in the CMS Open Payments database as having received $5,150 across 32 general payments and $666 in research payments paid to them. Separately, studies naming them as principal investigator received $3,011,909 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 95th percentile of General Practice profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $18 1
2023 General $4,884 17
2021 General $175 10
2020 General $50 3
2019 General $22 1
2019 Research $666 6

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Edgar Gonzalez
  • General Practice median
  • Middle half of General Practice
  • National median

In program year 2025, general payments to Edgar Gonzalez were reported at $18. Among 4,774 General Practice profiles paid that year, the median was $106 and the middle half received between $35 and $292.

Show as a table
Year Edgar Gonzalez General Practice median Middle half National median
2019 $22 $107 $37–$285 $163
2020 $50 $75 $25–$213 $114
2021 $175 $93 $30–$272 $132
2022 $0 $103 $36–$279 $149
2023 $4,884 $106 $34–$276 $160
2024 $0 $114 $39–$290 $164
2025 $18 $106 $35–$292 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Chiesi USA, Inc. $2,715 3 payments
  2. Alnylam Pharmaceuticals Inc. $1,162 9 payments
  3. Genentech USA, Inc. $859 3 payments
  4. Boehringer Ingelheim Pharmaceuticals, Inc. $150 2 payments
  5. AbbVie, Inc. $73 4 payments
  6. Novo Nordisk Inc $52 3 payments
  7. Janssen Pharmaceuticals, Inc $52 3 payments
  8. AstraZeneca Pharmaceuticals LP $34 2 payments
  9. Allergan Inc. $33 2 payments
  10. Gilead Sciences, Inc. $19 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Travel and Lodging $4,044 5 payments
  2. Food and Beverage $1,106 27 payments
Products named General payments · program years 2019–2025
  1. JARDIANCE $129 1 payment
  2. UBRELVY Neuroscience $68 4 payments
  3. XARELTO $52 3 payments
  4. FARXIGA $34 2 payments
  5. RYBELSUS $34 2 payments
  6. Ozempic $34 2 payments
  7. SPIRIVA RESPIMAT $22 1 payment
  8. VRAYLAR $21 1 payment
  9. Wegovy $18 1 payment
  10. UBRELVY Neuroscience $16 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Allergan Inc. $666 6 payments

Prescribing to Medicare patients

Part D · data year 2024 · 64 drugs

Part D claims

2,748

Median for Family Practice: 1,826

Drug cost

$132,425

Median for Family Practice: $120,094

Branded share of claims

13.4%

Median for Family Practice: 18.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Humira Pen Adalimumab Brand 11 $76,538
Eliquis Apixaban Brand 32 $28,985
Breyna Budesonide/Formoterol Fumarate Brand 14 $3,228
Tadalafil Generic 38 $2,328
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 11 $1,457
Atorvastatin Calcium Generic 192 $1,233
Omeprazole Generic 128 $1,221
Levothyroxine Sodium Generic 93 $951
Enalapril Maleate Generic 74 $940
Losartan Potassium Generic 84 $821

The 10 drugs with the highest cost, of 64 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 105,120 Part D prescribers listed as Family Practice; they describe a distribution and say nothing about conduct.

Records

38 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other General Practice in Florida

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record